Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hepatitis: HELP
Articles from Washington, DC
Based on 296 articles published since 2008
||||

These are the 296 published articles about Hepatitis that originated from Washington, DC during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12
1 Guideline Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. 2012

Yee, Helen S / Chang, Michael F / Pocha, Christine / Lim, Joseph / Ross, David / Morgan, Timothy R / Monto, Alexander / Anonymous1440724 / Anonymous1450724. ·Department of Veterans Affairs Hepatitis C Resource Center Program, Washington, DC, USA. ·Am J Gastroenterol · Pubmed #22525303.

ABSTRACT: Chronic hepatitis C virus (HCV) infection affects approximately 1.3 % of the United States population and 4 % of veterans who use Department of Veterans Affairs medical services. Chronic HCV is the primary cause of cirrhosis, hepatocellular carcinoma (HCC), and end-stage liver disease requiring liver transplantation in the United States. Management of chronic HCV is aimed at halting disease progression, preventing cirrhosis decompensation, reducing the risk of HCC, and treating extrahepatic complications of the infection. As part of a comprehensive HCV management strategy, peginterferon alfa and ribavirin, along with the addition of a hepatitis C protease inhibitor therapy for many genotype 1-infected patients, are the current standard of care. Antiviral therapy should be provided to those individuals who are clinically stable, have moderate liver disease or compensated cirrhosis, and are motivated to pursue therapy. Many patients have comorbid medical and psychiatric conditions, which may affect their adherence to antiviral therapy or worsen while on antiviral therapy. To optimally manage hepatitis C and associated comorbidities, patients benefit from multidisciplinary teams that can provide HCV-specific care and treatment. Sustained virologic response is associated with "cure" of chronic HCV, and results in improved liver disease outcomes and prolonged survival.

2 Editorial Challenges, Considerations, and Principles to Guide Trials of Combination Therapies for Chronic Hepatitis B Virus. 2019

Anderson, Ryan Taylor / Lim, Seng Gee / Mishra, Poonam / Josephson, Filip / Donaldson, Eric / Given, Bruce / Miller, Veronica. ·University of California, Berkeley, Washington, DC. · National University of Singapore, Singapore, Republic of Singapore. · US Food and Drug Administration, Silver Spring, Maryland. · Swedish Medical Products Agency, Uppsala, Sweden. · Arrowhead Pharmaceuticals, Inc., Pasadena, California. ·Gastroenterology · Pubmed #30529300.

ABSTRACT: -- No abstract --

3 Editorial Donor screening for hepatitis B: hepatitis B surface antigen-a belt, suspenders, and another belt? 2018

Katz, Louis M / Sayers, Merlyn. ·America's Blood Centers, Washington, DC. · University of Iowa Healthcare, Iowa City, Iowa. · Carter BloodCare. · University of Texas Southwestern, Dallas, Texas. ·Transfusion · Pubmed #30204949.

ABSTRACT: -- No abstract --

4 Editorial Preventing HIV and Hepatitis Infections Among People Who Inject Drugs: Leveraging an Indiana Outbreak Response to Break the Impasse. 2017

Crowley, Jeffrey S / Millett, Gregorio A. ·O'Neill Institute for National and Global Health Law, Georgetown University, 600 New Jersey Avenue, Washington, DC, 20001, USA. jeffrey.crowley@law.georgetown.edu. · amfAR, the Foundation for AIDS Research, Washington, DC, USA. ·AIDS Behav · Pubmed #28220312.

ABSTRACT: Providing clean needles through syringe services programs (SSPs) prevents the spread of disease among people who inject drugs (PWID). The recent HIV outbreak in Scott County, Indiana was a wakeup call with particular significance because modeling suggests that Scott County is but one of many counties in the United States highly vulnerable to an HIV outbreak among PWID. It is a painful recognition that some policy makers ignored the evidence in support of SSPs when it was primarily blacks in inner cities that were affected, yet swung into action in the wake of Scott County where 99% of the cases were white. Too many Americans have been taught to shame and shun drug users (irrespective or race or ethnicity). Therefore, we need lessons that afford benefits to all communities. We need to understand what made opinion leaders change their views and then change more hearts and minds before, not after the next outbreak.

5 Editorial Oxidative Stress and Inflammation in Hepatic Diseases: Current and Future Therapy. 2017

Reyes-Gordillo, Karina / Shah, Ruchi / Muriel, Pablo. ·Lipid Research Laboratory, VA Medical Center, 50 Irving Street NW, Washington, DC 20422, USA; Department of Biochemistry and Molecular Medicine, The George Washington University, 2300 I Street NW, Suite 530, Washington, DC 20037, USA. · Laboratory of Experimental Hepatology, Department of Pharmacology, Cinvestav-IPN, Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, 07360, Apartado Postal 14-740, 07000 México, DF, Mexico. ·Oxid Med Cell Longev · Pubmed #28203318.

ABSTRACT: -- No abstract --

6 Editorial A Convenient Truth: Cost of Medications Need Not Be a Barrier to Hepatitis B Treatment. 2016

Barnhart, Matthew. ·Global Health, Science and Practice, Associate Editor, Washington, DC, USA. ·Glob Health Sci Pract · Pubmed #27353613.

ABSTRACT: -- No abstract --

7 Review Five Questions Concerning Managing Hepatitis C in the Justice System: Finding Practical Solutions for Hepatitis C Virus Elimination. 2018

Spaulding, Anne C / Adee, Madeline G / Lawrence, Robert T / Chhatwal, Jagpreet / von Oehsen, William. ·Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road Room 3033, Atlanta, GA 30322, USA; Department of Medicine, Morehouse School of Medicine, 720 Westview Dr SW, Atlanta, GA 30310, USA. Electronic address: aspauld@emory.edu. · Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road Room 3033, Atlanta, GA 30322, USA. · Alaska Department of Corrections, 550 West 7th Avenue, Suite 1860, Anchorage, AK 99501, USA. · Institute for Technology Assessment, Massachusetts General Hospital, Harvard University, 101 Merrimac Street, Floor 10, Boston, MA 02114, USA. · Powers Pyles Sutter & Verville PC, 1501 M Street Northwest, Seventh Floor, Washington, DC 20005-1700, USA. ·Infect Dis Clin North Am · Pubmed #29778259.

ABSTRACT: An estimated 30% of Americans with hepatitis C virus (HCV) pass through a jail or prison annually. One in 7 incarcerated persons is viremic. Screening and treatment is cost-effective and beneficial to society as a whole. Yet at current (2018) levels of funding for HCV management, prisons are not aggressively seeking cases; few incarcerated persons with HCV actually receive treatment. This article explores barriers to screening for and treating hepatitis C in state prisons, and ways that states may overcome these barriers, such as nominal pricing. While high prices for direct-acting antivirals discourage treatment, potential strategies exist to lower prices.

8 Review Hepatitis C Care in the Department of Veterans Affairs: Building a Foundation for Success. 2018

Belperio, Pamela S / Chartier, Maggie / Gonzalez, Rachel I / Park, Angela M / Ross, David B / Morgan, Tim R / Backus, Lisa I. ·Patient Care Services/Population Health, Department of Veterans Affairs, Palo Alto Health Care System, 3801 Miranda Avenue (132), Palo Alto, CA 94304, USA. · HIV, Hepatitis and Related Conditions, Office of Specialty Care Services (10P11I), Department of Veterans Affairs, 810 Vermont Avenue, Washington, DC 20420, USA. · Research Health Care Group, VA Long Beach Health Care System, 5901 East 7th Street, Long Beach, CA 90822, USA. · New England Veterans Engineering Resource Center, Department of Veterans Affairs, 150 South Huntingtin Avenue, Boston, MA 02130, USA. · Division of Gastroenterology, VA Long Beach Health Care System, 5901 East 7th Street, Long Beach, CA 90822, USA. · Patient Care Services/Population Health, Department of Veterans Affairs, Palo Alto Health Care System, 3801 Miranda Avenue (132), Palo Alto, CA 94304, USA. Electronic address: Lisa.Backus@va.gov. ·Infect Dis Clin North Am · Pubmed #29778256.

ABSTRACT: The Department of Veterans Affairs (VA) has made significant progress in treating hepatitis C virus, experiencing more than a 75% reduction in veterans remaining to be treated since the availability of oral direct-acting antivirals. Hepatitis C Innovation Teams use lean process improvement and system redesign, resulting in practice models that address gaps in care. The key to success is creative improvements in veteran access to providers, including expanded use of nonphysician providers, video telehealth, and electronic technologies. Population health management tools monitor and identify trends in care, helping the VA tailor care and address barriers.

9 Review Ocular Manifestations of Mosquito-Transmitted Diseases. 2018

Karesh, James W / Mazzoli, Robert A / Heintz, Shannon K. ·The Vision Center of Excellence, Walter Reed National Military Medical Center, 8960 Brown Drive, Building 2, 1st Floor, Room 1403-A, Bethesda, MD 20889-5629. · The Vision Center of Excellence, Walter Reed National Military Medical Center, 8960 Brown Drive, Building 2, 1 st Floor, Room 1403-A, Bethesda, MD 20889-5629. · Madigan Army Medical Center, 9040 Jackson Avenue, Tacoma, WA 98431. ·Mil Med · Pubmed #29635625.

ABSTRACT: Of the 3,548 known mosquito species, about 100 transmit human diseases. Mosquitoes are distributed globally throughout tropical and temperate regions where standing water sources are available for egg laying and the maturation of larva. Female mosquitoes require blood meals for egg production. This is the main pathway for disease transmission. Mosquitoes carry several pathogenic organisms responsible for significant ocular pathology and vision loss including West Nile, Rift Valley, chikungunya, dengue viruses, various encephalitis viruses, malarial parasites, Francisella tularensis, microfilarial parasites, including Dirofilaria, Wuchereria, and Brugia spp., and human botfly larvae. Health care providers may not be familiar with many of these mosquito-transmitted diseases or their associated ocular findings delaying diagnosis, treatment, and recovery of visual function. This article aims to provide an overview of the ocular manifestations associated with mosquito-transmitted diseases.

10 Review Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B. 2018

Suslov, Aleksei / Wieland, Stefan / Menne, Stephan. ·Department of Biomedicine, University Hospital Basel, University of Basel, Basel CH-4031, Switzerland. · Department of Biomedicine, University Hospital Basel, University of Basel, Basel CH-4031, Switzerland. Electronic address: stefan.wieland@unibas.ch. · Department of Microbiology & Immunology, Georgetown University Medical Center, Washington, DC 20057, United States. Electronic address: Stephan.Menne@georgetown.edu. ·Curr Opin Virol · Pubmed #29444493.

ABSTRACT: The first line defense mechanisms against viral infection are mediated by the innate immune system. Viral components are detected by infected cells and/or innate immune cells that express different sensory receptors. They in turn mediate induction of direct antiviral mechanisms and further modulation of innate and adaptive immune responses. For evading the innate system, most viruses have evolved efficient mechanisms to block sensing and/or antiviral functions of the innate response. Interestingly, hepatitis B virus (HBV) seems to act like a stealth virus that escapes cell intrinsic antiviral mechanisms through avoiding recognition by the innate system rather than blocking its effector functions. In line with this concept, agonistic activation of innate immunity has emerged as a promising novel anti-HBV therapy approach with several compounds having advanced to the clinical stage.

11 Review Report from the International Conference on Viral Hepatitis - 2017. 2018

Soriano, Vicente / Young, Benjamin / Reau, Nancy. ·Infectious Diseases Unit, La Paz University Hospital, Madrid, Spain. · International Association of Providers of AIDS Care, Washington, DC, USA. · Liver Unit, Rush University Medical Center, Chicago, IL, USA. ·AIDS Rev · Pubmed #29369303.

ABSTRACT: The International Conference on Viral Hepatitis 2017 brought exciting news on the treatment of viral hepatitis. The most recent estimates of the burden for hepatitis B virus and hepatitis C virus (HCV) infections were presented. The current gaps and prospects for regional and global eradication of viral hepatitis were discussed on the light of the WHO roadmap until 2030. Debates focused on hepatitis C and expectations using the new approved HCV pan-genotypic, once daily, oral direct-acting antivirals (DAAs), glecaprevir-pibrentasvir, and sofosbuvir-velpatasvir-voxilaprevir. The management of difficult-to-cure HCV patients included individuals who had failed prior DAAs, people who inject drugs, patients with decompensated cirrhosis, or renal insufficiency. Special patient populations such as children, pregnant women, persons with acute hepatitis C, or HIV coinfection were addressed separately. The use of HCV treatment as prevention was subject to debate, balancing the benefits on halting transmission and the risk for HCV reinfections and high medication costs. Complementary efforts on behavioral interventions and harm reduction programs were highlighted. Data from both clinical trials and real-world experience (i.e., from the US Veterans) were compared. Further debates addressed hepatic conditions that may alter the management and outcome of viral hepatitis, such as hepatitis B reactivation, non-alcoholic fatty liver disease, liver transplantation, and hepatocellular carcinoma. Finally, the recent data on often neglected hepatitis D and E virus infections were reviewed.

12 Review Pathogen reduction and blood transfusion safety in Africa: strengths, limitations and challenges of implementation in low-resource settings. 2018

Ware, A D / Jacquot, C / Tobian, A A R / Gehrie, E A / Ness, P M / Bloch, E M. ·Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. · Children's National Health System and George Washington University School of Medicine and Health Sciences, Washington, DC, USA. ·Vox Sang · Pubmed #29193128.

ABSTRACT: Transfusion-transmitted infection risk remains an enduring challenge to blood safety in Africa. A high background incidence and prevalence of the major transfusion-transmitted infections (TTIs), dependence on high-risk donors to meet demand, suboptimal testing and quality assurance collectively contribute to the increased risk. With few exceptions, donor testing is confined to serological evaluation of human immunodeficiency virus (HIV), hepatitis B and C (HBV and HCV) and syphilis. Barriers to implementation of broader molecular methods include cost, limited infrastructure and lack of technical expertise. Pathogen reduction (PR), a term used to describe a variety of methods (e.g. solvent detergent treatment or photochemical activation) that may be applied to blood following collection, offers the means to diminish the infectious potential of multiple pathogens simultaneously. This is effective against different classes of pathogen, including the major TTIs where laboratory screening is already implemented (e.g. HIV, HBV and HCV) as well pathogens that are widely endemic yet remain unaddressed (e.g. malaria, bacterial contamination). We sought to review the available and emerging PR techniques and their potential application to resource-constrained parts of Africa, focusing on the advantages and disadvantages of such technologies. PR has been slow to be adopted even in high-income countries, primarily given the high costs of use. Logistical considerations, particularly in low-resourced parts of Africa, also raise concerns about practicality. Nonetheless, PR offers a rational, innovative strategy to contend with TTIs; technologies in development may well present a viable complement or even alternative to targeted screening in the future.

13 Review Mutation and recombination in pathogen evolution: Relevance, methods and controversies. 2018

Arenas, Miguel / Araujo, Natalia M / Branco, Catarina / Castelhano, Nadine / Castro-Nallar, Eduardo / Pérez-Losada, Marcos. ·Department of Biochemistry, Genetics and Immunology, University of Vigo, Vigo, Spain; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal. Electronic address: marenas@uvigo.es. · Laboratory of Molecular Virology, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil. Electronic address: nmaraujo@ioc.fiocruz.br. · Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal. Electronic address: cbranco@ipatimup.pt. · Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal. Electronic address: nadines@ipatimup.pt. · Universidad Andrés Bello, Center for Bioinformatics and Integrative Biology, Facultad de Ciencias Biológicas, Santiago, Chile. Electronic address: eduardo.castro@unab.cl. · Computational Biology Institute, Milken Institute School of Public Health, George Washington University, Ashburn, VA 20147, Washington, DC, United States; CIBIO-InBIO, Centro de Investigação em Biodiversidade e Recursos Genéticos, Universidade do Porto, Campus Agrário de Vairão, Vairão 4485-661, Portugal. Electronic address: mlosada@gwu.edu. ·Infect Genet Evol · Pubmed #28951202.

ABSTRACT: Mutation and recombination drive the evolution of most pathogens by generating the genetic variants upon which selection operates. Those variants can, for example, confer resistance to host immune systems and drug therapies or lead to epidemic outbreaks. Given their importance, diverse evolutionary studies have investigated the abundance and consequences of mutation and recombination in pathogen populations. However, some controversies persist regarding the contribution of each evolutionary force to the development of particular phenotypic observations (e.g., drug resistance). In this study, we revise the importance of mutation and recombination in the evolution of pathogens at both intra-host and inter-host levels. We also describe state-of-the-art analytical methodologies to detect and quantify these two evolutionary forces, including biases that are often ignored in evolutionary studies. Finally, we present some of our former studies involving pathogenic taxa where mutation and recombination played crucial roles in the recovery of pathogenic fitness, the generation of interspecific genetic diversity, or the design of centralized vaccines. This review also illustrates several common controversies and pitfalls in the analysis and in the evaluation and interpretation of mutation and recombination outcomes.

14 Review Historical epidemiology of hepatitis C virus in select countries-volume 4. 2017

Maaroufi, A / Vince, A / Himatt, S M / Mohamed, R / Fung, J / Opare-Sem, O / Workneh, A / Njouom, R / Al Ghazzawi, I / Abdulla, M / Kaliaskarova, K S / Owusu-Ofori, S / Abdelmageed, M K / Adda, D / Akin, O / Al Baqali, A / Al Dweik, N / Al Ejji, K / Al Kaabi, S / Al Naamani, K / Al Qamish, J / Al Sadadi, M / Al Salman, J / AlBadri, M / Al-Busafi, S A / Al-Romaihi, H E / Ampofo, W / Antonov, K / Anyaike, C / Arome, F / Bane, A / Blach, S / Borodo, M M / Brandon, S M / Bright, B / Butt, M T / Cardenas, I / Chan, H L Y / Chen, C J / Chen, D S / Chen, P J / Chien, R N / Chuang, W L / Cuellar, D / Derbala, M / Elbardiny, A A / Estes, C / Farag, E / Gamkrelidze, I / Garcia, V / Genov, J / Ghandour, Z / Ghuloom, M / Gomez, B / Gunter, J / Habeeb, J / Hajelssedig, O / Hamoudi, W / Hrstic, I / Hu, C C / Huang, C F / Hui, Y T / Jahis, R / Jelev, D / John, A K / Kamel, Y / Kao, J H / Khamis, J / Khattabi, H / Khoudri, I / Konysbekova, A / Kotzev, I / Lai, M S / Lao, W C / Layden, J / Lee, M H / Lesi, O / Li, M / Lo, A / Loo, C K / Lukšić, B / Malu, A O / Mateva, L / Mitova, R / Morović, M / Murphy, K / Mustapha, B / Nde, H / Nersesov, A / Ngige, E / Njoya, O / Nonković, D / Obekpa, S / Oguche, S / Okolo, E E / Omede, O / Omuemu, C / Ondoa, P / Phillips, R O / Prokopenko, Y N / Razavi, H / Razavi-Shearer, D / Redae, B / Reic, T / Rinke de Wit, T / Rios, C / Robbins, S / Roberts, L R / Sanad, S J / Schmelzer, J D / Sharma, M / Simonova, M / Su, T H / Sultan, K / Tan, S S / Tchernev, K / Tsang, O T Y / Tsang, S / Tzeuton, C / Ugoeze, S / Uzochukwu, B / Vi, R / Wani, H U / Wong, V W S / Yacoub, R / Yesmembetov, K I / Youbi, M / Yuen, M F / Razavi-Shearer, K. ·National Institute of Health Administration, Rabat, Morocco. · Medical School University of Zagreb, University Hospital of Infectious Diseases Zagreb, Zagreb, Croatia. · Ministry of Public Health Qatar, Doha, Qatar. · University of Malaya Medical Centre, Kuala Lumpur, Malaysia. · Department of Medicine, The University of Hong Kong, Hong Kong, SAR, China. · Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. · Non-Communicable Diseases Programme, World Health Organization, Addis Ababa, Ethiopia. · Federal Ministry of Health, Addis Ababa, Ethiopia. · Virology Department, Centre Pasteur of Cameroon, Yaounde, Cameroon. · GI and Hepatology Department, Jordan Royal Medical Services, Amman, Jordan. · Salmaniya Medical Complex, Manama, Bahrain. · Ministry of Healthcare and Social Development of the Republic of Kazakhstan, Astana, Kazakhstan. · Republican Coordination Center for Hepatology and Gastroenterology, Astana, Kazakhstan. · Komfo Anokye Teaching Hospital, Kumasi, Ghana. · Hamad Medical Corporation, Doha, Qatar. · Civil Society Network on Hepatitis, Abuja, Nigeria. · Chagro-Care Trust (CCT), Jalingo, Nigeria. · Federal Ministry of Health, Abuja, Nigeria. · Al Kindi Specialised Hospital, Manama, Bahrain. · Division of Gastroenterology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar. · Division of Gastroenterology and Hepatology, Department of Medicine, Armed Forces Hospital, Muscat, Oman. · Gastroenterolgy Clinic, IBN Al-Nafees Hospital, Manama, Bahrain. · Division of Gastroenterology, Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman. · Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana. · University Hospital "St. Ivan Rilski", Sofia, Bulgaria. · Advocacy for the Prevention of Hepatitis in Nigeria, Jos, Nigeria. · Gastroenterology and Hepatology, Addis Ababa University Medical School, Addis Ababa, Ethiopia. · Ethiopian Gastroenterological Association, Addis Ababa, Ethiopia. · Center for Disease Analysis (CDA), Lafayette, CO, USA. · Aminu Kano Teaching Hospital, Kano, Nigeria. · Bayero University, Kano, Nigeria. · LiveWell Initiative (LWI), Lagos, Nigeria. · Communicable Diseases Division, Ministry of Health and Social Protection, Bogota, Colombia. · Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, SAR, China. · Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, SAR, China. · Academia Sinica, Taipei, Taiwan. · Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan. · National Taiwan University, Taipei, Taiwan. · Liver Research Unit, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan. · Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan. · Department of Epidemiology and Demography, Ministry of Health and Social Protection, Bogota, Colombia. · Ministry of Public Health, Santo Domingo, Dominican Republic. · University Hospital "Queen Joanna", Sofia, Bulgaria. · BDF Hospital, Royal Medical Services, Riffa, Bahrain. · Pan American Health Organization, Washington, DC, USA. · Department of Gastroenterology & Hepatology, Al Bashir Hospital, Amman, Jordan. · Jordan Ministry of Health, Amman, Jordan. · General Hospital Pula, Pula, Croatia. · Department of Medicine, Queen Elizabeth Hospital, Hong Kong, SAR, China. · Disease Control Division, Ministry of Health, Putrajaya, Malaysia. · Department of Medicine, Miniya University, Minya, Egypt. · Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan. · Eastern Mediterranean Regional Office, World Health Organization, Cairo, Egypt. · Republican Diagnostic Center, Astana, Kazakhstan. · University Medical Center, Astana, Kazakhstan. · University Hospital "St. Marina", Varna, Bulgaria. · Department of Medicine, North District Hospital, Hong Kong, SAR, China. · Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong, SAR, China. · Department of Public Health Sciences, Loyola University Chicago, Chicago, IL, USA. · Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. · University of Lagos, Lagos, Nigeria. · Lagos University Teaching Hospital, Lagos, Nigeria. · Division of Gastroenterology and Hepatology, Department of Medicine and Geriatrics, Tuen Mun Hospital, Hong Kong, SAR, China. · Department of Medicine and Geriatrics, Kwong Wah Hospital, Hong Kong, SAR, China. · Clinical Department of Infectious Diseases, Split University Hospital and Split University Medical School, Split, Croatia. · Benue State University Teaching Hospital, Makurdi, Nigeria. · Department of Infectious Diseases, Zadar General Hospital, Zadar, Croatia. · IBN SINA Hospital, Rabat, Morocco. · National Research Institute of Cardiology and Internal Diseases, Almaty, Kazakhstan. · Research Laboratory on Viral Hepatitis & Health Communication, Faculty of Medicine, University of Yaoundé, Yaoundé, Cameroon. · Department of Epidemiology, Institute of Public Health, County of Dalmatia, Split, Croatia. · Department of Pediatrics, University of Jos, Jos, Nigeria. · Department of Medicine, University of Jos, Jos, Nigeria. · Jos University Teaching Hospital, Jos, Nigeria. · Beacon Youth Initiative, Lafia, Nigeria. · University of Benin, Benin City, Nigeria. · Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands. · African Society of Laboratory Medicine, Addis Ababa, Ethiopia. · St. Paul's Hospital Millennium College, Addis Ababa, Ethiopia. · European Liver Patients Association, Sint-Truiden, Belgium. · PharmAccess Foundation, Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. · Department of Health Promotion and Disease Prevention, Ministry of Health and Social Protection, Bogota, Colombia. · Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. · Clinic of Gastroenterology, Military Medical Academy, Sofia, Bulgaria. · Department of Hepatology, Selayang Hospital, Selangor, Malaysia. · "Sofiamed" Hospital, Sofia, Bulgaria. · Department of Medicine and Geriatrics, Princess Margaret Hospital Authority, Hong Kong, SAR, China. · Department of Medicine, Tseung Kwan O Hospital, Hong Kong, SAR, China. · Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon. · Federal Medical Centre, Jalingo, Nigeria. · Institute of Public Health, University of Nigeria, Nsukka, Nigeria. · International HepatoTransplant Group, Astana, Kazakhstan. · State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, SAR, China. · National Scientific Center of Oncology and Transplantology, Astana, Kazakhstan. · Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, SAR, China. ·J Viral Hepat · Pubmed #29105285.

ABSTRACT: Due to the introduction of newer, more efficacious treatment options, there is a pressing need for policy makers and public health officials to develop or adapt national hepatitis C virus (HCV) control strategies to the changing epidemiological landscape. To do so, detailed, country-specific data are needed to characterize the burden of chronic HCV infection. In this study of 17 countries, a literature review of published and unpublished data on HCV prevalence, viraemia, genotype, age and gender distribution, liver transplants and diagnosis and treatment rates was conducted, and inputs were validated by expert consensus in each country. Viraemic prevalence in this study ranged from 0.2% in Hong Kong to 2.4% in Taiwan, while the largest viraemic populations were in Nigeria (2 597 000 cases) and Taiwan (569 000 cases). Diagnosis, treatment and liver transplant rates varied widely across the countries included in this analysis, as did the availability of reliable data. Addressing data gaps will be critical for the development of future strategies to manage and minimize the disease burden of hepatitis C.

15 Review Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues. 2017

Wu, Tiffany / Kwok, Ryan M / Tran, Tram T. ·Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA. · Division of Gastroenterology and Hepatology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA. · Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA. ·Am J Gastroenterol · Pubmed #29087395.

ABSTRACT: Hepatitis B core antibody (anti-HBc) is considered the most sensitive serological marker for history of hepatitis B virus (HBV) infection. In a subset of anti-HBc carriers, anti-HBc is present in the absence of hepatitis B surface antigen and hepatitis B surface antibody-a serological pattern known as "isolated anti-HBc" (IAHBc). IAHBc has been of clinical interest over the past several years, with growing data to suggest its role as a serological marker for occult HBV infection (OBI). This article reviews the clinical significance and association of IAHBc with hepatitis C virus (HCV) co-infection, risk of HBV reactivation during direct-acting antiviral therapy for HCV as well as immune suppression, and development of hepatocellular carcinoma (HCC). Hepatitis B core-related antigen is also highlighted as an emerging laboratory assay that may identify OBI and predict HCC development in non-cirrhotic patients receiving nucleoside/nucleotide analog therapy.

16 Review Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B. 2017

Hong, Xupeng / Kim, Elena S / Guo, Haitao. ·Department of Microbiology and Immunology, Georgetown University Medical Center, Washington, DC. · Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN. ·Hepatology · Pubmed #28833361.

ABSTRACT: Hepatitis B virus (HBV) infection represents a significant public health burden worldwide. Although current therapeutics manage to control the disease progression, lifelong treatment and surveillance are required because drug resistance develops during treatment and reactivations frequently occur following medication cessation. Thus, the occurrence of hepatocellular carcinoma is decreased, but not eliminated. One major reason for failure of HBV treatment is the inability to eradicate or inactivate the viral covalently closed circular DNA (cccDNA), which is a stable episomal form of the viral genome decorated with host histones and nonhistone proteins. Accumulating evidence suggests that epigenetic modifications of cccDNA contribute to viral replication and the outcome of chronic HBV infection. Here, we summarize current progress on HBV epigenetics research and the therapeutic implications for chronic HBV infection by learning from the epigenetic therapies for cancer and other viral diseases, which may open a new venue to cure chronic hepatitis B. (Hepatology 2017;66:2066-2077).

17 Review Economic Burden of Hepatitis C Infection. 2017

Stepanova, Maria / Younossi, Zobair M. ·Center for Outcomes Research in Liver Diseases, 2411 I Street NW, Washington, DC 20037, USA; Betty and Guy Beatty Center for Integrated Research, Inova Health System, 3300 Gallows Road, Falls Church, VA 22042, USA. · Center for Outcomes Research in Liver Diseases, 2411 I Street NW, Washington, DC 20037, USA; Betty and Guy Beatty Center for Integrated Research, Inova Health System, 3300 Gallows Road, Falls Church, VA 22042, USA; Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA. Electronic address: zobair.younossi@inova.org. ·Clin Liver Dis · Pubmed #28689595.

ABSTRACT: The economic burden of chronic hepatitis C might exceed $10 billion annually in the United States alone. This disease has a worldwide prevalence of up to 3%, making the global burden of the disease comparably tremendous. The cost of the disease includes direct medical expenses for its hepatic and extrahepatic manifestations, and also indirect costs incurred from impaired quality of life and the loss of work productivity. Recent emergence of treatment options that are not only highly effective and safe but also costly has emphasized the need to study the disease from the economic point of view.

18 Review Drugs in Development for Hepatitis B. 2017

Dawood, Altaf / Abdul Basit, Syed / Jayaraj, Mahendran / Gish, Robert G. ·Department of Internal Medicine, Section of Gastroenterology, University of Nevada School of Medicine, Las Vegas, NV, USA. · Department of Internal Medicine, Section of Gastroenterology, University of Nevada School of Medicine, Las Vegas, NV, USA. rgish@robertgish.com. · Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Stanford, CA, USA. rgish@robertgish.com. · Hepatitis B Foundation, Doylestown, PA, USA. rgish@robertgish.com. · Asian Pacific Health Foundation, San Diego, CA, USA. rgish@robertgish.com. · National Viral Hepatitis Roundtable, Washington, DC, USA. rgish@robertgish.com. ·Drugs · Pubmed #28660478.

ABSTRACT: With high morbidity and mortality worldwide, there is great interest in effective therapies for chronic hepatitis B (CHB) virus. There are currently several dozen investigational agents being developed for treatment of CHB. They can be broadly divided into two categories: (1) direct-acting antivirals (DAAs) that interfere with a specific step in viral replication; and (2) host-targeting agents that inhibit viral replication by modifying host cell function, with the latter group further divided into the subcategories of immune modulators and agents that target other host functions. Included among the DAAs being developed are RNA interference therapies, covalently closed circular DNA (cccDNA) formation and transcription inhibitors, core/capsid inhibitors, reverse transcriptase inhibitors, hepatitis B surface antigen (HBsAg) release inhibitors, antisense oligonucleotides, and helioxanthin analogues. Included among the host-targeting agents are entry inhibitors, cyclophilin inhibitors, and multiple immunomodulatory agents, including Toll-like receptor agonists, immune checkpoint inhibitors, therapeutic vaccines, engineered T cells, and several cytokine agents, including recombinant human interleukin-7 (CYT107) and SB 9200, a novel therapy that is believed to both have direct antiviral properties and to induce endogenous interferon. In this review we discuss agents that are currently in the clinical stage of development for CHB treatment as well as strategies and agents currently at the evaluation and discovery phase and potential future targets. Effective approaches to CHB may require suppression of viral replication combined with one or more host-targeting agents. Some of the recent research advances have led to the hope that with such a combined approach we may have a functional cure for CHB in the not distant future.

19 Review Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage. 2017

Neuman, Manuela G / French, Samuel W / Zakhari, Samir / Malnick, Stephen / Seitz, Helmut K / Cohen, Lawrence B / Salaspuro, Mikko / Voinea-Griffin, Andreea / Barasch, Andrei / Kirpich, Irina A / Thomes, Paul G / Schrum, Laura W / Donohue, Terrence M / Kharbanda, Kusum K / Cruz, Marcus / Opris, Mihai. ·In Vitro Drug Safety and Biotechnology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: manuela.neuman@utoronto.ca. · Harbor-UCLA Medical Center, Torrance, CA, USA. · Distilled Spirits Council, Washington, DC, USA. · Department Internal Medicine, Kaplan Medical Centre and Hebrew University of Jerusalem, Rehovot, Israel. · Centre of Alcohol Research, University of Heidelberg, Heidelberg, Germany. · Division of Gastroenterology, Sunnybrook Health Sciences Centre, Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. · Research Unit on Acetaldehyde and Cancer, University of Helsinki, Helsinki, Finland. · Public Health Science Texas A&M University, College of Dentistry, Dallas University, TX, USA. · Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, NY, USA. · Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USA; Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY, USA. · Department of Internal Medicine, Carolinas Medical Center, Charlotte, NC, USA; Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. · Department of Internal Medicine, Carolinas Medical Center, Charlotte, NC, USA. · Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. · Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA; Research Service, Veterans Affairs Nebraska-Western Iowa Health Care System, University of Nebraska Medical Center, Omaha, NE, USA; Department of Biochemistry & Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA. · In Vitro Drug Safety and Biotechnology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. · Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Family Medicine Clinic CAR, Bucharest, Romania. ·Exp Mol Pathol · Pubmed #28077318.

ABSTRACT: This paper is based upon the "8th Charles Lieber's Satellite Symposium" organized by Manuela G. Neuman at the Research Society on Alcoholism Annual Meeting, on June 25, 2016 at New Orleans, Louisiana, USA. The integrative symposium investigated different aspects of alcohol-induced liver disease (ALD) as well as non-alcohol-induced liver disease (NAFLD) and possible repair. We revealed the basic aspects of alcohol metabolism that may be responsible for the development of liver disease as well as the factors that determine the amount, frequency and which type of alcohol misuse leads to liver and gastrointestinal diseases. We aimed to (1) describe the immuno-pathology of ALD, (2) examine the role of genetics in the development of alcoholic hepatitis (ASH) and NAFLD, (3) propose diagnostic markers of ASH and non-alcoholic steatohepatitis (NASH), (4) examine age and ethnic differences as well as analyze the validity of some models, (5) develop common research tools and biomarkers to study alcohol-induced effects, 6) examine the role of alcohol in oral health and colon and gastrointestinal cancer and (7) focus on factors that aggravate the severity of organ-damage. The present review includes pre-clinical, translational and clinical research that characterizes ALD and NAFLD. Strong clinical and experimental evidence lead to recognition of the key toxic role of alcohol in the pathogenesis of ALD with simple fatty infiltrations and chronic alcoholic hepatitis with hepatic fibrosis or cirrhosis. These latter stages may also be associated with a number of cellular and histological changes, including the presence of Mallory's hyaline, megamitochondria, or perivenular and perisinusoidal fibrosis. Genetic polymorphisms of ethanol metabolizing enzymes and cytochrome p450 (CYP) 2E1 activation may change the severity of ASH and NASH. Other risk factors such as its co-morbidities with chronic viral hepatitis in the presence or absence of human deficiency virus were discussed. Dysregulation of metabolism, as a result of ethanol exposure, in the intestine leads to colon carcinogenesis. The hepatotoxic effects of ethanol undermine the contribution of malnutrition to the liver injury. Dietary interventions such as micro and macronutrients, as well as changes to the microbiota have been suggested. The clinical aspects of NASH, as part of the metabolic syndrome in the aging population, have been presented. The symposium addressed mechanisms and biomarkers of alcohol induced damage to different organs, as well as the role of the microbiome in this dialog. The microbiota regulates and acts as a key element in harmonizing immune responses at intestinal mucosal surfaces. It is known that microbiota is an inducer of proinflammatory T helper 17 cells and regulatory T cells in the intestine. The signals at the sites of inflammation mediate recruitment and differentiation in order to remove inflammatory inducers and promote tissue homeostasis restoration. The change in the intestinal microbiota also influences the change in obesity and regresses the liver steatosis. Evidence on the positive role of moderate alcohol consumption on heart and metabolic diseases as well on reducing steatosis have been looked up. Moreover nutrition as a therapeutic intervention in alcoholic liver disease has been discussed. In addition to the original data, we searched the literature (2008-2016) for the latest publication on the described subjects. In order to obtain the updated data we used the usual engines (Pub Med and Google Scholar). The intention of the eighth symposia was to advance the international profile of the biological research on alcoholism. We also wish to further our mission of leading the forum to progress the science and practice of translational research in alcoholism.

20 Review Hepatitis B and Risk of Non-Hepatocellular Carcinoma Malignancy. 2016

Kwok, Ryan M / Tran, Tram T. ·Gastroenterology Fellowship Program, Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20889, USA. Electronic address: ryan.m.kwok.mil@mail.mil. · Gastroenterology Fellowship Program, Cedars Sinai Medical Center, Geffen School of Medicine at University of California Los Angeles, 8900 Beverly Boulevard, Los Angeles, CA 90048, USA. ·Clin Liver Dis · Pubmed #27742008.

ABSTRACT: Chronic hepatitis B infection (CHB) is a known risk factor for malignancy. Unlike hepatocellular carcinoma (HCC), less is known about the risk of non-HCC malignancy. However, epidemiology and pathologic evidence suggests a strong association between non-Hodgkin lymphoma and CHB. Data regarding the risk of other malignancies, such as pancreatic adenocarcinoma and intrahepatic cholangiocarcinoma, are mixed. Surveillance and appropriate treatment of infection and malignancy in these patients is essential. Further study of these associations is needed and may bring new insights in the pathogenesis and treatment of these diseases.

21 Review Medical co-morbidities of patients with haemophilia: pain, obesity and hepatitis C. 2016

Witkop, M L / Peerlinck, K / Luxon, B A. ·Northern Regional Bleeding Disorders Center, Munson Medical Center, Traverse City, MI, USA. · Department of Vascular Medicine and Haemostasis, Haemophilia Centre University Hospitals, Leuven, Belgium. · Department of Medicine, Georgetown University, Washington, DC, USA. ·Haemophilia · Pubmed #27405676.

ABSTRACT: Clinical care of patients with haemophilia (PWH) has progressed rapidly over the past decade. Current therapy has allowed patients with haemophilia to live longer and many patients are now experiencing the co-morbidities of the general population. In this review article, we focus on three common diseases states that affect PWH: chronic pain, obesity and hepatitis C. Pain has been a co-morbidity for many years and PWH often have unusual needs for chronic pain relief compared to the general population. Obesity is not only increasing in the general population but also in patients with hereditary bleeding disorders. The co-morbidity of obesity not only causes increased pain progression and joint damage but also affects the dosing of factor concentrates. Finally, hepatitis C is known to have infected the majority of patients who received non-virally inactivated pooled factor concentrates in the past. New treatment regimens have been developed that allow the nearly uniform cure of chronic hepatitis C with a short course of oral medications.

22 Review Public health and international drug policy. 2016

Csete, Joanne / Kamarulzaman, Adeeba / Kazatchkine, Michel / Altice, Frederick / Balicki, Marek / Buxton, Julia / Cepeda, Javier / Comfort, Megan / Goosby, Eric / Goulão, João / Hart, Carl / Kerr, Thomas / Lajous, Alejandro Madrazo / Lewis, Stephen / Martin, Natasha / Mejía, Daniel / Camacho, Adriana / Mathieson, David / Obot, Isidore / Ogunrombi, Adeolu / Sherman, Susan / Stone, Jack / Vallath, Nandini / Vickerman, Peter / Zábranský, Tomáš / Beyrer, Chris. ·Columbia University, New York City, NY, USA. · University of Malaya, Kuala Lumpur, Malaysia. · UN Special Envoy, HIV in Eastern Europe and Central Asia, Geneva, Switzerland. · Yale University, New Haven, CT, USA. · Warsaw, Poland. · Central European University, Budapest, Hungary. · Center for Public Health and Human Rights, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. · RTI International, Washington, DC, USA. · University of California, San Francisco, San Francisco, CA, USA. · Ministry of Health, Lisbon, Portugal. · University of British Columbia, Center of Excellence in HIV/AIDS, Vancouver, BC, Canada. · Centro de Investigación y Docencia Económicas, Mexico City, Mexico. · AIDS-Free World, Toronto, ON, Canada. · University of California, San Diego, San Diego, CA, USA. · University of the Andes, Bogotá, Colombia. · Human Rights Watch, Yangon, Myanmar. · University of Uyo, Uyo, Nigeria. · Youth Rise-Nigeria, Lagos, Nigeria. · University of Bristol, Bristol, UK. · Trivandrum Institute of Palliative Sciences, Trivandrum, India. · Charles University, Prague, Czech Republic. · Center for Public Health and Human Rights, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: cbeyrer@jhu.edu. ·Lancet · Pubmed #27021149.

ABSTRACT: -- No abstract --

23 Review Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. 2016

Younossi, Zobair / Park, Haesuk / Henry, Linda / Adeyemi, Ayoade / Stepanova, Maria. ·Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, Virginia; Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia. Electronic address: zobair.younossi@inova.org. · University of Florida College of Pharmacy, Gainesville, Florida. · Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia. · Center for Outcomes Research in Liver Diseases, Washington, District of Columbia. ·Gastroenterology · Pubmed #26924097.

ABSTRACT: BACKGROUND & AIMS: Hepatitis C virus (HCV) infection has hepatic and extrahepatic manifestations with various costs and impairments to health-related quality of life (HRQL). We performed a meta-analysis to determine the prevalence of extrahepatic manifestations in patients with HCV infection, how these impair HRQL, and their costs. METHODS: We performed systematic reviews of the literature using MEDLINE, CINAHL, and the Cochrane Systematic Review Database, from 1996 through December 2014, to identify studies of the following extrahepatic manifestations of HCV infection: mixed cryoglobulinemia, chronic kidney or end-stage renal disease, type 2 diabetes, B-cell lymphoma, lichen planus, Sjögren's syndrome, porphyria cutanea tarda, rheumatoid-like arthritis, or depression. We performed a separate meta-analysis for each condition to determine prevalence rates of extrahepatic manifestations of HCV infection and their effects on HRQL. We determined the annual costs (inpatient, outpatient, and pharmacy) associated with extrahepatic manifestations of HCV infection. RESULTS: In an analysis of data from 102 studies, we found the most common extrahepatic manifestations to be diabetes (in 15% of patients) and depression (in 25% of patients). HRQL data showed that HCV infection had negative effects on overall physical and mental health. Total direct medical costs of extrahepatic manifestations of HCV infection, in 2014 US dollars, were estimated to be $1506 million (range, $922 million-$2208 million in sensitivity analysis). CONCLUSIONS: In a systematic review and meta-analysis we determined the prevalence, risks, and costs associated with extrahepatic manifestations of HCV infection. These estimates should be added to the liver-related burden of disease to obtain a more accurate assessment of the total burden of chronic HCV infection. Prospective, real-world studies are needed to increase our understanding of the total clinical and economic effects of HCV infection and treatment on patients and society.

24 Review The American College of Preventive Medicine Position Statement on Hepatitis C Virus Infection. 2016

Allison, Robert D / Hale, Steven A / Harvey, Bart J / Hudson, Toni-Marie L / Livingston, Catherine J / Sherin, Kevin M / Uduhiri, Kelechi A / Niebuhr, David W / Anonymous610859. ·Department of Preventive Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. · Department of Family Medicine & Rural Health, University of Central Florida College of Medicine, Orlando, Florida; Florida Department of Health in Orange County, Orlando, Florida. · Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. · Florida Department of Health in Orange County, Orlando, Florida. · Department of Family Medicine, Oregon Health and Science University, Portland, Oregon. · Department of Family Medicine & Rural Health, University of Central Florida College of Medicine, Orlando, Florida; Florida Department of Health in Orange County, Orlando, Florida; Florida State University College of Medicine, Tallahassee, Florida. · Department of Family Medicine, Providence Hospital, Washington, District of Columbia. · Department of Preventive Medicine and Biostatistics, Uniformed Services University of Health Sciences, Bethesda, Maryland. Electronic address: david.niebuhr@usuhs.edu. ·Am J Prev Med · Pubmed #26897344.

ABSTRACT: The American College of Preventive Medicine Prevention Practice Committee contributes to policy guidelines and recommendations on preventive health topics for clinicians and public health decision makers. After review of the currently available evidence, the College is providing a consensus-based set of recommendations designed to increase screening for and prevention of hepatitis C virus infection, increase linkage to care, improve access to treatment, and encourage development of hepatitis C virus-related quality measures.

25 Review Current treatment options for hepatitis C patients co-infected with HIV. 2016

Rockstroh, Jürgen Kurt / Hardy, W David. ·a Department of Medicine I , Bonn University Hospital , Bonn , Germany. · b German Centre for Infection Research (DZIF) , Partner Site Bonn-Cologne , Bonn , Germany. · c Whitman-Walker Health , Washington , DC , USA. ·Expert Rev Gastroenterol Hepatol · Pubmed #26799571.

ABSTRACT: With the availability of all-oral, direct acting antivirals (DAAs), hepatitis C virus (HCV) therapy has been revolutionized for HIV/HCV co-infected patients. Indeed HCV cure rates are now no longer different between HCV mono and HIV/HCV co-infected persons and are both greater than 95%. Therefore, current treatment guidelines no longer separate these two groups. Indications for HCV treatment and choice of DAA combination are now the same for all HCV patients. In HIV/HCV co-infection however, drug interactions between HIV and HCV agents need be checked prior to starting HCV therapy. Finally, the higher risk of hepatic decompensation in HIV/HCV co-infected patients, including those receiving successful antiretroviral therapy, continues to make these patients a high priority group for receiving access to modern DAA combination therapy.

Next